Skip to main content
PharmaBlock Sciences (Nanjing), Inc. logo

PharmaBlock Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 300725 ISIN · CNE1000035K5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2025-04-24 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300725

About PharmaBlock Sciences (Nanjing), Inc.

https://www.pharmablock.com

PharmaBlock Sciences (Nanjing), Inc. specializes in the design and manufacture of innovative building blocks and provides integrated chemistry services for drug discovery and development. The company offers a comprehensive portfolio of structurally diverse scaffolds and intermediates used to enhance the efficiency of medicinal chemistry. Its core capabilities include process research and development, scale-up production, and commercial-scale manufacturing under CDMO frameworks. By utilizing advanced chemical technologies and a vast library of unique chemical entities, the company supports global biotechnology and pharmaceutical organizations in streamlining their research pipelines and optimizing the transition from discovery to clinical development and commercialization.

Recent filings

Filing Released Lang Actions
监事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the fourth meeting of the fourth Supervisory Board of Nanjing Yaoshi Technology Co., Ltd. It includes multiple agenda items such as approval of the 2024 Annual Report, 2024 Annual Financial Report, 2024 Audit Report, 2024 Supervisory Board Work Report, 2024 Internal Control Self-Evaluation Report, 2024 Internal Control Audit Report, 2025 Q1 Report, and other corporate governance and financial matters. The document repeatedly states that the actual reports are published separately on the official disclosure website (cninfo.com.cn) and that the Supervisory Board has reviewed and approved these reports and proposals to be submitted to the shareholders' meeting. The document itself is a formal meeting resolution announcement, not the reports themselves. It is a regulatory announcement of board/committee meeting decisions and approvals, not a full financial report or audit report. Therefore, the best fitting category is Board/Management Information (MANG), as it relates to supervisory board meeting resolutions and approvals of reports and corporate actions.
2025-04-24 Chinese
2024年度独立董事述职报告（高允斌，已届满离任）
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of 南京药石科技股份有限公司 for the year 2024. It includes the director's background, attendance at meetings, committee work, communication with auditors, on-site work, protection of investor rights, and overall evaluation and suggestions. The content focuses on governance, oversight, and compliance activities throughout the year, which aligns with a Management Report or Board/Management Information. It is not a full annual report (10-K) or audit report, nor is it a brief announcement or presentation. The document is over 6000 characters and contains substantive content about the director's duties and activities during the year, which fits best under Board/Management Information (MANG).
2025-04-24 Chinese
2024年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2024 年度财务决算报告' which translates to '2024 Annual Financial Settlement Report'. It contains detailed financial data for the full fiscal year 2024, including income statement, balance sheet, cash flow statement, and notes on changes in assets, liabilities, equity, and profit components. It also mentions an audit report with an unqualified opinion by a certified accounting firm. The length of the document (8504 characters) and the presence of comprehensive financial statements and analysis confirm it is a full annual financial report. There is no indication that this is merely an announcement or a certification letter. Therefore, this document fits the definition of an Annual Report (10-K).
2025-04-24 Chinese
2024 年度募集资金存放与实际使用情况专项报告的鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2024年度募集资金存放与实际使用情况专项报告的鉴证报告" which translates to "2024 Annual Special Report on the Custody and Actual Use of Raised Funds with an Assurance Report." It includes detailed financial data on the amount of funds raised, their usage, management, and changes in investment projects. The document also contains an auditor's assurance report verifying the accuracy and compliance of the special report with regulatory requirements. The presence of detailed financial tables, auditor's opinion, and compliance with China Securities Regulatory Commission guidelines indicates this is a standalone audit or assurance report related to the use of raised funds, not a full annual report or a simple announcement. It is not a general annual report (10-K), nor a brief announcement or presentation. It is a specialized audit/assurance report on fundraising usage, fitting the definition of Audit Report / Information (AR). The document length (13,805 characters) and detailed content confirm it is the report itself, not just an announcement. Therefore, the correct classification is AR with high confidence.
2025-04-24 Chinese
华泰联合证券有限责任公司关于南京药石科技股份有限公司部分募集资金投资项目重新论证的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from Huatai United Securities Co., Ltd., acting as the sponsor for Nanjing Yaoshi Technology Co., Ltd., regarding the re-evaluation of certain fundraising investment projects. It discusses the 2020 private placement of shares, the use and progress of the raised funds, reasons for delays in project progress, feasibility and necessity of the projects, and the approval process by the board and supervisory committee. The document includes detailed financial figures related to fundraising and investment projects, and it is a formal verification and opinion report rather than a full annual or interim financial report. It is not a simple announcement or a certification letter but a comprehensive verification opinion related to fundraising projects. This fits best under the category of Capital/Financing Update (CAP), as it deals with fundraising, use of proceeds, and investment project re-evaluation tied to capital raised through a private placement. The document length (4544 characters) is sufficient to contain substantive content, not just an announcement. Therefore, the classification is CAP with high confidence.
2025-04-24 Chinese
2024年年度财务报告
Annual Report Classification · 100% confidence The document is titled "南京药石科技股份有限公司2024 年年度财务报告" which translates to "Nanjing Yaoshi Technology Co., Ltd. 2024 Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the fiscal year ending December 31, 2024. The length of the document is about 15,000 characters, indicating a full report rather than a brief announcement. The content includes comprehensive financial data and analysis typical of an annual report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K).
2025-04-24 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.